USA Archives

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 28 Oct 2022

AKT inhibitor shows signs of effectiveness in patient trial

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Oct 2022

Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation

This week, we have three interviews, and four guests. We chatted with Keith Fargo, chief scientific officer at the CMT Research Foundation; François Colery, head of the Talent Now initiative and Sylvie Ponchaut, managing director, from BioWin; and e-therapeutics’ CEO, Ali Mortazavi. We also have our weekly contribution from global commercial real estate services company […]

October 28, 2022

cancer cell screening drug discovery microplate

News and Trends 26 Oct 2022

Recursion announces $150M private placement

U.S. biotech Recursion Pharmaceuticals has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement. It was led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management. The […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

Opinion 25 Oct 2022

Precision medicine research must lose its Eurocentricity

Precision medicine research relies on genetic testing at scale, but how do we reach more diverse patient populations and collect nationally representative samples? Patrick Short, CEO and co-founder of Sano Genetics, and Natasha Ratcliffe, director of community engagement and partnerships at Couch Health, explain how Eurocentricity is holding back genetics, and what can be done. […]

October 25, 2022 - 7 minutesmins - By External Contributor

In Depth 20 Oct 2022

Opportunities and challenges for cell and gene therapy investments

Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […]

October 20, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 20 Oct 2022

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Partnership formed to make drug for MoCD Type A available sooner

Inceptua Early Access and Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company bringing therapies to patients living with rare diseases, have entered into a partnership. The partnership is to make Sentynl’s Nulibry available via an early access program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is a rapidly progressive autosomal […]

October 20, 2022 - 2 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 20 Oct 2022

Healthy volunteer study for tablet to treat brain cancer open for recruitment

A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for a pharmacokinetic / pharmacodynamic trial in healthy volunteers (HV). Evgen Pharma plc also announced the start an investigator sponsored clinical study (ISS) for a glioblastoma program. The purpose of the HV study is to examine the performance of Evgen’s new […]

October 20, 2022 - 4 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Multi-year agreement to boost women’s reproductive health

A multi-year agreement between BioSkryb Genomics and Cooper Genomics, a reproductive health company was announced yesterday (October 18). The agreement is to license BioSkyrb’s proprietary genomic amplification technology. Cooper will utilize the Bioskryb technology to enhance their preimplantation genetic testing (PGT) capabilities. The agreement will also allow Cooper to boost BioSkyrb’s tech for the PGT […]

October 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Report says 20% of global cancer deaths could be avoided

A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […]

October 19, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Empyrean Neuroscience launches with $22M to target CNS disorders

Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

AKT inhibitor shows signs of effectiveness in patient trial

Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation

Recursion announces $150M private placement

Precision medicine research must lose its Eurocentricity

Opportunities and challenges for cell and gene therapy investments

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

AbbVie acquires LifeArc portfolio company DJS Antibodies

Partnership formed to make drug for MoCD Type A available sooner

Healthy volunteer study for tablet to treat brain cancer open for recruitment

Multi-year agreement to boost women’s reproductive health

Report says 20% of global cancer deaths could be avoided

Empyrean Neuroscience launches with $22M to target CNS disorders

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!